BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a buy rating in a report released on Thursday, January 11th.
Other analysts have also issued research reports about the stock. Canaccord Genuity reaffirmed a buy rating on shares of Atara Biotherapeutics in a report on Friday, December 29th. Jefferies Group reissued a buy rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, October 5th. ValuEngine raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a report on Friday, December 29th. Citigroup raised shares of Atara Biotherapeutics from a sell rating to a neutral rating and set a $18.00 price target for the company in a report on Wednesday, January 3rd. Finally, Goldman Sachs Group reissued a neutral rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $30.60.
Atara Biotherapeutics (NASDAQ ATRA) traded down $2.90 during midday trading on Thursday, hitting $33.05. 1,166,151 shares of the stock traded hands, compared to its average volume of 1,260,000. The firm has a market capitalization of $1,010.00, a price-to-earnings ratio of -9.52 and a beta of 2.71. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $40.75.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). research analysts forecast that Atara Biotherapeutics will post -4 earnings per share for the current year.
In other Atara Biotherapeutics news, EVP Gad Soffer sold 7,000 shares of Atara Biotherapeutics stock in a transaction on Friday, November 17th. The shares were sold at an average price of $15.00, for a total transaction of $105,000.00. Following the completion of the sale, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 48,500 shares of Atara Biotherapeutics stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $34.58, for a total transaction of $1,677,130.00. Following the sale, the chief executive officer now directly owns 348,978 shares of the company’s stock, valued at approximately $12,067,659.24. The disclosure for this sale can be found here. In the last three months, insiders sold 264,088 shares of company stock valued at $6,442,371. 16.20% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Atara Biotherapeutics during the third quarter worth $142,000. Russell Investments Group Ltd. bought a new position in shares of Atara Biotherapeutics during the third quarter worth $170,000. Voya Investment Management LLC boosted its position in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Atara Biotherapeutics during the second quarter worth $252,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares in the last quarter. 69.71% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Upgraded to “Buy” by BidaskClub” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/02/atara-biotherapeutics-atra-lifted-to-buy-at-bidaskclub.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.